gimli
GLENMARK stock analysis context
GLENMARK PHARMACEUTICALS Stock Context for AI Screening
GLENMARK PHARMACEUTICALS is a mid-cap stock in Healthcare. This page summarizes key screening signals for GLENMARK PHARMACEUTICALS, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about GLENMARKPrice
₹2,259.10
1M return
+0.85%
3M return
+10.57%
Market cap
₹63,751.98 cr
PE
59.86
ROE
+12.76%
RSI
44.66
Turnover
₹360.09 cr
Why it can matter in screens
- Momentum: GLENMARK is above 50DMA, above 200DMA; RSI is 44.66.
- Returns: 1M +0.85%, 3M +10.57%, 6M +22.50%.
- Liquidity: latest turnover is ₹360.09 cr.
- Valuation: PE 59.86, PB n/a, ROE +12.76%, ROCE +18.02%.
- Growth: 3Y sales CAGR +2.59%, 3Y profit CAGR +3.60%.
Try these prompts
- Analyze GLENMARK PHARMACEUTICALS with valuation, momentum and industry peers
- Compare GLENMARK with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare GLENMARK with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.